Stockscreener 앱 받기
4.20
4.55%
-0.20
시간 외 거래:
4.20
전일 마감가:
$4.40
열려 있는:
$4.25
하루 거래량:
3,960
Relative Volume:
0.09
시가총액:
$6.24M
수익:
$61,000
순이익/손실:
$-5.46M
주가수익비율:
-0.6422
EPS:
-6.54
순현금흐름:
$-6.76M
1주 성능:
-5.62%
1개월 성능:
-8.70%
6개월 성능:
+28.83%
1년 성능:
-24.60%
1일 변동 폭
$4.17
$4.40
1주일 범위
$4.17
$4.6499
52주 변동 폭
$3.03
$14.80
타이탄 파마슈티컬스 Stock (TTNP) Company Profile
명칭
Titan Pharmaceuticals Inc De
전화
(650) 244-4990
주소
400 OYSTER POINT BLVD, SAN FRANCISCO
TTNP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TTNP
Titan Pharmaceuticals Inc De
|
4.20 | 6.24M | 61,000 | -5.46M | -6.76M | -6.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.20 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
525.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
326.09 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
551.22 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
242.07 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
타이탄 파마슈티컬스 Stock (TTNP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2019-06-26 | 개시 | Maxim Group | Buy |
| 2017-11-10 | 다운그레이드 | ROTH Capital | Buy → Neutral |
타이탄 파마슈티컬스 주식(TTNP)의 최신 뉴스
Lobe Sciences Secures $26M for Novel Chronic Cluster Headache Drug Development | LOBEF Stock News - Stock Titan
Biotech to Environmental Services: Windtree's $12M Revenue Play in $85B Waste Management Market - Stock Titan
Titan Medical (NASDAQ:TMDIF) Stock Price Down 2.4% – Here’s Why - Defense World
Merger Alert: Titan Pharmaceuticals Takes Major Step Toward TalenTec Combination with Critical SEC Filing - Stock Titan
Biotech to AI: Bionoid Pharma Makes Bold Pivot with New Identity as AI Maverick Intel - Stock Titan
Clinical Data: Vanda Unveils Key Bioequivalence Study Results for Next-Gen Psychiatric Drug at Major Conference - Stock Titan
Biotech Rising Star Conduit Pharmaceuticals Gets Green Light for Nasdaq Capital Market Transfer - Stock Titan
Petros Pharmaceuticals Faces NASDAQ Delisting Despite $10M Cash Position, Plans Appeal - Stock Titan
Conduit Pharmaceuticals Secures Future on Nasdaq: Clears Both Bid Price and Equity Hurdles - Stock Titan
Conduit Pharma Sets 15:1 Reverse Split: Shares Drop to 755,900 Starting May 20 - Stock Titan
Biotech Company Makes Bold Leap into AI: Bionoid Pharma Rebrands as AI Maverick Intel - Stock Titan
HOPE Therapeutics Lands $7.8M Deal to Build National Mental Health Network with Ketamine Treatment Centers - Stock Titan
Regeneron Secures Massive $407M Victory: Jury Finds Amgen Guilty of Illegal PCSK9 Drug Bundling Scheme - Stock Titan
Acurx Pharmaceuticals, Inc. Reports First Quarter Results and Provides Business Update - Stock Titan
HOPE Therapeutics, Inc. and NRx Pharmaceuticals (NASDAQ:NRXP) Announce Signing of Definitive Agreement to Purchase Kadima Neuropsychiatry Institute; Foundational Acquisition for the HOPE Network of Interventional Psychiatry Clinics - Stock Titan
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report First Quarter 2025 Financial Results on May 15, 2025 - Stock Titan
Conduit Pharmaceuticals Receives Further Patent Approval For Its Lead Asset Targeting Autoimmune Diseases - Stock Titan
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results - Stock Titan
CYCLACEL PHARMACEUTICALS ANNOUNCES STOCK SPLIT | CYCC Stock News - Stock Titan
NRXP Reveals Major Mental Health Expansion Plans at Exclusive Mar-A-Lago Investor Event - Stock Titan
Citius Pharmaceuticals Reveals Growth Strategy at Major Jefferies Healthcare Conference - Stock Titan
Biotech Firm Terns Awards Massive 325,000 Share Options Package to New Key Hires - Stock Titan
Generic Percocet Launch: Elite Pharmaceuticals Targets $317M Pain Management Market - Stock Titan
Trump Executive Order Validates Petros' AI Technology Platform for Revolutionary Drug Access Reform - Stock Titan
Heron Therapeutics Strengthens Leadership: Former Veloxis CEO Takes COO Role with Major Stock Package - Stock Titan
Nordic Pharma Enters $20.8M Eye Medicine Market with Generic Maxitrol Launch via Harrow Partnership - Stock Titan
X4 Pharmaceuticals Strengthens Team with 450,000 Share Options Grant: Inside the Retention Plan - Stock Titan
Major UK Retail Breakthrough: Sonoma's Natural Acne Treatment to Roll Out Across 1,200 Leading Pharmacies - Stock Titan
Jazz's $935M Chimerix Buyout Targets First-Ever Treatment for Rare Brain Cancer, FDA Verdict Looms - Stock Titan
Vincerx Pharma Announces Complete Liquidation and Nasdaq Exit: What Happens to Your Shares? - Stock Titan
Strategic Win: Phathom Taps 30-Year Pharma Veteran to Drive VOQUEZNA Commercial Success - Stock Titan
Major Kidney Disease Drug Acquisition: Rege Nephro Takes Over Syros' Phase 2 Asset - Stock Titan
US Stocks Likely To Open Higher: Expert Says 'The Selling Pressure Is Starting To Be Exhausted' - Benzinga
Titan Pharma Lands Crucial $1M Backing: Inside the Strategic Investment Deal - Stock Titan
Clinical Data: Nika's ITV-1 Drug Demonstrates Breakthrough Effects in Multiple Diseases - Stock Titan
Keros Eyes Potential Sale: Board Weighs Strategic Options Amid Investor Interest - Stock Titan
Strategic Board Shake-Up: Ex-Pharma CFO and Former Congressman Join Titan Environmental's Expansion Push - Stock Titan
Failed Merger Forces Vincerx Pharma to Begin Company Wind-Down: What's Next for Investors? - Stock Titan
Arrowhead Pharmaceuticals Expands Team with 34,190 RSU Grants to New Hires - Stock Titan
Rigel Strengthens Biotech Team: Strategic Stock Grants Attract Key Talent - Stock Titan
Strategic $2.5M Investment Values Mental Health Clinic Network at $50M: Major Expansion Ahead - Stock Titan
Dogwood Therapeutics Saves Nasdaq Status: $17.5M Cash, Zero Debt After Major Financial Overhaul - Stock Titan
Key Investor Update: Lexicon Pharma Takes Stage at Elite Needham Healthcare Conference - Stock Titan
Citius Secures Strategic $2M Funding to Accelerate LYMPHIR LaunchKey Details Revealed - Stock Titan
NRx Pharmaceuticals Lands Revenue-Generating Mental Health Clinic in Strategic Veterans Care Push - Stock Titan
Exclusive: ANI Pharmaceuticals CEO Reveals Growth Strategy at Major Ophthalmology Conference - Stock Titan
Lexicon's Game-Changing Obesity Drug Catches Novo Nordisk's Eye in Billion-Dollar Deal - Stock Titan
aTyr Pharma Strengthens Drug Development Team with New Equity Compensation Package - Stock Titan
Actinium Reveals 3 Breakthrough Programs Targeting Billion-Dollar Markets at Mar-a-Lago Update - Stock Titan
Actinium Expands into $B Market: Expert Reveals Breakthrough Cancer Programs - Stock Titan
$10M Capital Raise: TransCode Therapeutics Accelerates TTX-MC138 Clinical Trials - StockTitan
타이탄 파마슈티컬스 (TTNP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.78%
0.23%
자본화:
|
볼륨(24시간):